The series is stated in the current share scale after splits; dividends are not included in the price
ResMed makes machines and masks for treating sleep apnoea — breathing interruptions the patient usually does not suspect.
The machine delivers pressurised air and lasts for years, while masks, tubing and filters are replaced regularly — hence recurring revenue that grows with the installed base. Only a minority of those who have the condition are diagnosed, and that sets a long horizon for the market's growth.
The company pairs the hardware with software that tracks whether the patient actually uses the machine: both the treatment outcome and the insurer's payment depend on it. A separate story of recent years is weight-loss drugs: the market feared that weight loss would shrink the patient pool, whereas the data so far shows the opposite. ResMed pays a dividend.
Based on the fiscal year ended 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.